3P Biopharmaceuticals and SpyBiotech Sign Vaccine Manufacturing Agreement

Contract development and manufacturing organization (CDMO), 3P Biopharmaceuticals, and Oxford University spin-out, SpyBiotech, have signed a vaccine contract manufacturing agreement, it was announced in an Oct. 26, 2020 press release.

SpyBiotech’s SpyCatcher/SpyTag platform technology enables antigens to be displayed onto virus-like particles with a covalent, irreversible bond in a stable and effective way with specific orientation/epitope presentation and high density. The company states that the technology has broad applicability in vaccine development and has established proof of concept data in viral, bacterial, parasitic diseases, chronic diseases, and cancer.

In June 2019, SpyBiotech selected 3P Biopharmaceuticals for the manufacture of a current good manufacturing practice (CGMP) batch of its virus-like particle carrier, with the aim for production to be completed in 2021. Through this latest agreement, 3P Biopharmaceuticals will demonstrate its capacity to perform processes and manufacturing of molecules developed for diverse therapeutic applications.

“It is amazing being part of a project which presents an opportunity to develop treatments for a broad range of diseases,” said Dámaso Molero, CEO of 3P Biopharmaceuticals, in the press release. “We are helping to support manufacturing which we believe will open the door for pioneering vaccines which could offer a hope for improving the lives of many people. That is extremely exciting.”

Genevieve Labbe, senior scientist and GMP project manager for SpyBiotech added in the press release, “It’s critical to have a trusted partner in place for cell line and CGMP production. SpyBiotech is looking forward to advancing this product and we are delighted to be working with 3P Biopharmaceuticals.”

Source: 3P Biopharmaceuticals​